Abstract Body

Background: HCV NS3/4A protease inhibitors (PIs) are proven therapeutic agents used in treating chronic HCV infection. First generation PIs (boceprevir or telaprevir), when combined with pegylated interferon and ribavirin (P/R), improve the cure rate in patients harboring HCV genotype (GT) 1 infections. Their usage, however, is limited by the emergence of drug resistant variants during treatment, and their lower potency against several other HCV GTs. In addition, these agents must be combined with P/R, which leads to significant side effects in treated patients. We report here the preclinical virological characterization of ABT-493, a next generation PI identified as a lead compound by AbbVie and Enanta, with potent activity across HCV GTs, and activity against the major resistant variants selected by other PIs currently in clinical development. Methodology: The antiviral potency of ABT-493 was evaluated in assays using subgenomic HCV replicons expressing wild-type or common drug-resistant variant proteases from a number of HCV GTs. In addition, the resistance profile of ABT-493 was determined by colony selection in replicons containing GT 1a, 1b, or 3a protease. Results: ABT-493 inhibited replication of HCV stable subgenomic replicons containing NS3 genes from GT 1a, 1b, 2a, 3a, 4a, or 6a with EC50 values ranging from 0.85 to 2.8 nM. Of note, ABT-493 was potent against replicon containing GT3a protease, with an EC50 value of 1.6 nM. ABT-493 retained its activity against common GT1a and 1b variants at NS3 amino acid positions 155 and 168 that conferred resistance to other HCV PIs. Resistant colony selection studies in GT1a and 1b subgenomic replicon cells identified A156T in GT1a and A156V in GT1b as the most frequent variants, which conferred 1400- and 1800-fold reduced susceptibility to ABT-493, respectively. However, these variants had in vitro replication capacities of only 1.5% and 9.2% that of their corresponding wild-type replicons. In a replicon containing GT3a NS3 protease, ABT-493 selected very few colonies at concentrations ≥ 100-fold over its EC50 value. The colonies that survived the selection contained either A156G alone, or Q168R co-selected with Y56H, which conferred 1500- or 1100-fold loss in susceptibility to ABT-493, respectively. Conclusions: Based on its preclinical profile, ABT-493 is anticipated to have broad genotype coverage and be active against most of the clinically important drug resistant variants selected by other PIs in GT1. It is, therefore, an excellent drug candidate to be included in the development of a directacting antiviral regimen for the treatment of chronic HCV infection.